Aquestive Therapeutics, Inc. — Director's Dealing 2020

Jun 18, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Aquestive Therapeutics, Inc. (AQST)
CIK: 0001398733
Period of Report: 2020-06-16

Reporting Person: BRATTON DOUGLAS K (N/A)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-06-16	Stock Option (Right to Purchase)	$5.30	A	14000	Acquired	2030-06-16	Common Stock (14000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	75085	Direct
Common Stock	165000	Indirect
Common Stock	2249077	Indirect
Common Stock	2213314	Indirect
Common Stock	4032907	Indirect
Common Stock	2755541	Indirect
Common Stock	87455	Indirect

Footnotes

F1: These securities are beneficially owned by MonoLine Partners, L.P. ("MonoLine").

F2: These securities are owned, as indicated, by MonoLine, MRX Partners, LLC ("MRX Partners"), MonoLine Rx, L.P. ("Monoline Rx"), MonoLine Rx II, L.P. ("Monoline II"), and MonoLine Rx III, L.P. ("Monoline III"), respectively. Monoline, MRX Partners, Monoline Rx, Monoline II, and Monoline III are referred to herein collectively as the "Monoline Entities". Bratton Capital Management, L.P. ("Bratton Capital Management") is the general partner of each of the Monoline Entities. Bratton Capital, Inc. ("Bratton") is the general partner of Bratton Capital Management. The Reporting Person, Douglas K. Bratton, is the sole director of Bratton and has voting and investment power over all shares held by the Monoline Entities.

F3: Bratton Capital Management, Bratton, and Mr. Bratton may each be deemed to own beneficially all shares owned by the Monoline Entities, and Bratton and Mr. Bratton may be deemed to beneficially own all shares held by Monosol. Each such entity and Mr. Bratton disclaims beneficial ownership of the reported securities except to the extent of its or his respective pecuniary interest therein.

F4: These securities are beneficially owned by MRX Partners.

F5: These securities are beneficially owned by Monoline Rx.

F6: These securities are beneficially owned by Monoline II.

F7: These securities are beneficially owned by Monoline III.

F8: These securities are beneficially owned by MonoSol Rx Genpar, L.P. ("Monosol"). Bratton is the general partner of Monosol. The Reporting Person, Douglas K. Bratton, is the sole director of Bratton and has voting and investment power over all shares held by Monosol.

F9: The shares underlying the options vest as follows: 100% of the underlying shares vest June 16, 2021, subject to Mr. Bratton's continuous service with the Issuer from the grant date through the applicable vesting date.